News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
Seres Therapeutics (MCRB) Craters in Phase II ECOSPOR Study; CEO and Execs Profit on Insider Sales 7/29/2016
Neurocrine Biosciences (NBIX) Announces Initiation Of A Long-Term Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Tourette Syndrome 7/29/2016
Shire (SHPG)'s SHP626 Granted FDA Fast Track Designation As Investigational Treatment In NASH With Liver Fibrosis 7/29/2016
Biophytis Receives Approval Of Bpifrance For An Innovation Loan Of €1.1 Million To Finance The SARA-PK Trial 7/29/2016
Quark Pharmaceuticals Inc. Awarded Key Patent For QPI-1007 Ocular Neuroprotectant 7/29/2016
Eli Lilly (LLY) Release: New Studies Suggest Relationship Between Tau Pathology And Progression Of Alzheimer's Disease 7/28/2016
Oramed (ORMP) Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering Of Glucose Levels Vs Placebo 7/28/2016
Anavex (AVXL) Plummeted on Phase IIa Alzheimer's Results "Considered" Positive 7/28/2016
Chase Pharma Presents Phase 2 Results For CPC-201 At 2016 Alzheimer’s Association International Conference 7/28/2016
Chugai Pharma's Emicizumab Showed Continued Benefits In Patients With Hemophilia A 7/28/2016
vTv Therapeutics Announces Presentation Of Phase 2b Azeliragon Results At The 2016 Alzheimer’s Association International Conference (AAIC) 7/28/2016
Millendo Therapeutics Announces Publication Of Positive Phase 2a Data For MLE4901 For The Treatment Of Polycystic Ovary Syndrome 7/28/2016
Caladrius Biosciences (CLBS) Receives FDA Fast Track Designation For CLBS03 To Treat Recent Onset Type 1 Diabetes 7/28/2016
Agenus (AGEN) Reports Second Quarter 2016 Financial Results And Operational Progress 7/28/2016
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets 7/28/2016
Karyopharm (KPTI) To Present Updated Phase II Clinical Data From SIGN Study At European Society Of Medical Oncology 2016 Annual Meeting 7/28/2016
Neurovance Announces Positive Centanafadine Phase 2b Results For Adult ADHD, And Plans For Phase 3 Trials 7/27/2016
Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source 7/27/2016
LSK BioPharma Announces Successful Outcome From End-Of-Phase 2 Meeting With FDA 7/26/2016
Poxel Announces Publication Of Important New Mechanism Data For Imeglimin Relating To Insulin Secretion In The Treatment Of Type 2 Diabetes 7/26/2016
Parion Sciences Announces Initiation Of Phase II Clinical Trial Of P-321 For The Treatment Of Dry Eye Disease 7/26/2016
BrightFocus Foundation Release: Health-Ebrain Study To Launch Phase II 7/26/2016
Flex Pharma (FLKS) Completes Enrollment Of Human Proof-Of Concept Efficacy Study In Nocturnal Leg Cramps 7/26/2016
Eisai Inc. (ESALF.PK) And Halozyme (HALO) Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 7/26/2016
Janssen Biotech (JNJ) Announces Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Immuno-Oncology Combination In Lung Cancer 7/26/2016
BioInvent (BOVNF) Interim Report 1 January – 30 June 2016 7/26/2016
Synthetic Biologics (SYN) To Report Second Quarter 2016 Operational Highlights And Financial Results On August 3, 2016 7/26/2016
Gradalis Inc. Appoints Martin J. Birkhofer, M.D. Chief Medical Officer 7/26/2016
Tobira (TBRA) Stock Loses More Than Half Its Value After Phase IIb Trial Miss 7/25/2016
Vtesse Bags Another $17 Million to Support Further Product Development and Expand Ongoing Clinical Trials 7/25/2016
Merck & Co. (MRK) Nabs Breakthrough Tag for Ebola Zaire Vaccine From the FDA and PRIME Status From EMA 7/25/2016
Can-Fite BioPharma (CFBI) Completes Phase II Study Design For CF102 In The Treatment Of NASH/NAFLD 7/25/2016
Eiger Biopharma Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema 7/25/2016
PTC Therapeutics (PTCT) Provides Regulatory Update On Translarna (Ataluren) 7/25/2016
Tobira (TBRA) To Host Conference Call At 8:30 A.M. Eastern Time Tomorrow To Discuss CENTAUR Phase 2b Trial Results 7/25/2016
Why Investors Should Pay Attention to Seattle Genetics (SGEN)' Drug Trial 7/22/2016
ViaCyte Awarded New CIRM Grant To Develop PEC-Direct For High-Risk Type 1 Diabetes 7/22/2016
Diversity Of Eli Lilly (LLY)'s Alzheimer's Disease Pipeline Showcased At The Alzheimer's Association International Conference 2016 (AAIC 2016) 7/21/2016
DNAtrix, Inc. Announces Successful Intratumoral Delivery Of DNX-2401 Via Alcyone's MEMS Cannula For The Targeted Treatment Of Recurrent Glioblastoma 7/21/2016
Advaxis (ADXS)’ AXAL Receives Fast Track Designation By The FDA As Adjuvant Therapy For High-Risk Locally Advanced Cervical Cancer Patients 7/21/2016
Rhythm Announces The New England Journal of Medicine Publication Of Setmelanotide Phase 2 Data For Treatment Of POMC Deficiency Obesity 7/21/2016
Novan Announces First Patient Dosed In Phase 2 Anti-Fungal Program 7/21/2016
CytoDyn (CYDY) Submits Orphan Drug Application To FDA For Pretreatment With PRO 140 Of Treatment-Naïve HIV Patients 7/21/2016
BioPharmX Study Shows BPX-01 Topical Gel Delivers Minocycline Precisely To The Skin 7/21/2016
Hansa Medical Interim Report April – June 2016 7/21/2016
Eiger Biopharma Announces Completion Of Dosing In Phase 2 LOWR HDV - 3 Study At NIH 7/20/2016
Cell Medica Release: Lead Cancer Immunotherapy Candidate Granted EU Orphan Drug Designations 7/20/2016
CytoDyn (CYDY) Submits Protocol for Phase IIb Trial for Treatment Naïve HIV Patients 7/19/2016
Cerulean Pharma Inc. (CERU) Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer 7/19/2016
Hansa Medical Initiates Pivotal Multicenter Study In The U.S. With Ides For Treatment Of Refractory Highly Sensitized Kidney Patients 7/19/2016
Antibe Therapeutics (ATE.V) Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346 7/19/2016
Juno (JUNO) Stock Falls Again After Correcting Number of Trial Deaths 7/18/2016
Soligenix (SNGX) Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation 7/18/2016
BrainStorm Cell Announces Positive Top Line Results From The U.S. Phase 2 Study Of NurOwn In Patients With Amyotrophic Lateral Sclerosis (ALS) 7/18/2016
Seattle Genetics (SGEN) And Takeda (TKPYY) Announce Publication Of Final Data From ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase II Clinical Trial In Relapsed Or Refractory Classical Hodgkin Lymphoma In Blood 7/18/2016
Eiger Biopharma Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension 7/18/2016
HYD Receives Ethical Approval For Phase 2 Clinical Trial Investigating The Anticancer Effect Of Deuterium Depletion In CLL 7/18/2016
Armagen Presents Data From First Cohort Of Phase 1/2a Of AGT-182 For Treatment Of Hunter Syndrome 7/15/2016
Panther Biotechnology Announces The Initiation Of Formal Development Of Transferrin Doxorubicin Conjugate 7/15/2016
BrainStorm Cell To Announce Top Line Results From The U.S. Phase 2 Study of NurOwn In Patients With Amyotrophic Lateral Sclerosis (ALS) On Monday, July 18 7/15/2016
SAGE Therapeutics (SAGE)' Stock Explodes as Drug Eliminates Postpartum Depression in Mid-Stage Study 7/14/2016
Juno (JUNO) Soars After the FDA OKs Restart of Clinical Trial 7/14/2016
vTv Therapeutics Announces Phase IIb Azeliragon Data Selected For Oral Presentation At The 2016 Alzheimer’s Association International Conference 7/14/2016
Enteris Biopharma Initiates Clinical Program For Tobrate (Oral Tobramycin Tablet) In Uncomplicated Urinary Tract Infection 7/13/2016
Akari Therapeutics Receives Approval From The UK Medicines & Healthcare Products Regulatory Agency To Conduct Phase II Trial In Paroxysmal Nocturnal Hemoglobinuria 7/13/2016
Agile Therapeutics, Inc. Announces Plans To Advance Contraceptive Pipeline 7/13/2016
Inotek Pharmaceuticals Corporation (ITEK) Initiates Phase 2 Dose-ranging Trial Of A Fixed-Dose Combination Of Trabodenoson, A Novel Treatment For Glaucoma, And Latanoprost 7/13/2016
3 Nauseating Clinical Trial Flops of 2016 So Far 7/12/2016
Aviragen Resumes Enrollment In Phase IIa RSV Challenge Trial 7/12/2016
Asterias Biotherapeutics Completes Enrollment And Dosing For The First Efficacy Cohort Of The AST-OPC1 Scistar Phase 1/2a Clinical Trial In Complete Cervical Spinal Cord Injury 7/12/2016
Synthetic Biologics (SYN) Announces Granting Of European And U.S. Composition Of Matter Patents For Ribaxamase 7/12/2016
Juno (JUNO) Halts CAR-T Cancer Trial After Three Patient Deaths 7/11/2016
In Juno (JUNO) Patient Deaths, Echoes Seen Of Earlier Failed Company Dendreon (DNDN) 7/11/2016
Sucampo (SCMP) Terminates Development of Cobiprostone Following Phase II Data 7/11/2016
AbbVie (ABBV) Receives U.S. FDA Rare Pediatric Disease Designation For Investigational ABT-414 For The Treatment Of A Type Of Pediatric Brain Tumor Known As Diffuse Intrinsic Pontine Glioma (DIPG) 7/11/2016
NLS Pharma Group Release: Mazindol Granted Orphan Drug Designation In The US & Europe For Treatment Of Narcolepsy 7/11/2016
AbbVie (ABBV)'s $175 Million Gamble Pays Off as Ablynx (ABLYF) RA Drug Meets Goal in Phase II Study 7/8/2016
Pfizer (PFE) Stock Climbs With Positive Renal Cancer Phase III Data 7/8/2016
Alnylam (ALNY) Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection 7/8/2016
Kite Pharma (KITE) Completes Enrollment Of All Patients With Diffuse Large B-Cell Lymphoma (DLBCL) In Pivotal Multi-Center Phase 2 Study Of KTE-C19 (ZUMA-1) 7/8/2016
Ionis Pharma (IONS) Reports Positive Clinical Data On IONIS-TTR Rx At The XV International Symposium On Amyloidosis 7/7/2016
Puma Biotech (PBYI) Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal of Medicine 7/7/2016
ColonaryConcepts Successfully Completes Phase II Study For A New Approach To Colonoscopy Prep For Colorectal Cancer Screening 7/7/2016
Juniper Pharma (JNP) Announces Completion Of Enrollment In Phase 2b Clinical Trial Of COL-1077 10% Lidocaine Vaginal Gel For Gynecologic Procedure Pain 7/7/2016
Synthetic Biologics (SYN) Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004 7/7/2016
Catabasis (CATB) Announces The Initiation Of An Open-Label Extension For The Movedmd Trial Studying Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy 7/7/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far! 7/6/2016
Sanofi Genzyme (SNY) Begins Pivotal Phase II/III Trial Of Olipudase Alfa For Adult Patients With Acid Sphingomyelinase Deficiency 7/6/2016
FDA Grants Merrimack (MACK) Fast Track Designation For Seribantumab (MM-121) In Non-Small Cell Lung Cancer 7/6/2016
RiboMed Biotechnologies, Inc. And Tocagen Inc. Collaborate To Analyze Epigenetic Prognostic Markers, Including MGMT, In Recurrent Brain Tumors 7/6/2016
OphthaliX Inc. Announces Phase II Glaucoma Data 7/5/2016
NeuroDerm (NDRM) Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 7/1/2016
Shire (SHPG)'s Retinopathy Treatment Fails to Meet Primary Endpoint in Phase II 7/1/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal 6/30/2016
Novartis AG (NVS) PKC412 (Midostaurin) Pivotal Data Published In The New England Journal of Medicine Show 60% Response Rate In Advanced Systemic Mastocytosis (SM) 6/30/2016
Global Blood Therapeutics (GBT) Announces Initiation Of Phase 2a Study Of GBT440 In Adolescents With Sickle Cell Disease 6/30/2016
Poxel SAS Announces Patient Enrollment Completed For Imeglimin Phase 2b Clinical Trial In Type 2 Diabetes In Japan 6/30/2016
Zytoprotec GmbH Completes Enrollment In Phase II Study With Novel Peritoneal Dialysis Fluid 6/30/2016
BioMarker Strategies Awarded Phase I/II Fast Track National Cancer Institute Grant To Develop Companion Diagnostic Test To Select Optimal Therapy For Patients With Non-Small Cell Lung Cancer 6/30/2016
AbbVie (ABBV) Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease 6/29/2016
BioPharmX Announces Positive Topline Phase 2a Clinical Trial Results For BPX-01 In Patients With Acne-Causing Bacteria 6/29/2016
Aurinia (ISA.TO) Announces 24 Week Remission Rates From The First Seven Patients In Its Open Label AURION Study In Lupus Nephritis (LN) 6/29/2016
New Kid Vidac Pharma Completes $9 Million Series A Financing; Advances Phase II VDA-1102 6/29/2016
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 2 Study In Female Patients With Colorectal Cancer Metastatic To The Liver 6/29/2016
Janssen Pharmaceutical Companies Release: Ibrutinib (IMBRUVICA) Granted Breakthrough Therapy Designation By FDA For The Development Of A Treatment For Chronic Graft-Versus-Host Disease (cGVHD) 6/29/2016
NeuroDerm (NDRM) Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA In Head-To-Head Pilot PK Comparison Trial 6/29/2016
Marinus Pharma (MRNS)'s Primary Endpoint Not Met in Ganaxolone Phase II 6/28/2016
Zynerba (ZYNE) Announces Positive Top Line Results From ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial And Initiation Of Phase 2 Study In Adult Epilepsy Patients With Refractory Focal Seizures 6/28/2016
Bristol-Myers Squibb (BMY)'s Miracle Drug Opdivo Receives Yet Another Breakthrough Designation 6/28/2016
Immune Pharma Release: New Data Suggests Improved Tumor Response For The Combination of AZIXA and Immune Checkpoint Inhibitors in The Treatment of Cancer 6/28/2016
Mologen (MOLGF.PK): First Patients Enrolled In Extension Phase Of The HIV Study TEACH 6/28/2016
BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA (Pembrolizumab) For Treatment Of Pancreatic Cancer 6/28/2016
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 2 Portion Of Clinical Trial Of GMI-1271 In Newly Diagnosed Acute Myeloid Leukemia 6/28/2016
Ablynx (ABLYF) To Exercise Option To License Vectura (VEC.L)’s FOX Device For Use In Its Forthcoming Phase IIb Efficacy Study Of Its Inhaled Anti-RSV Nanobody (ALX-0171) 6/28/2016
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6 6/28/2016
Xencor Provides Updates On Lead Programs And Reviews Bispecific Oncology Partnership; Announces Expansion Of Bispecific Oncology Pipeline At Analyst Day 6/28/2016
Allergy Therapeutics Phase II Fails to Find Hay Fever Therapy Dose Range 6/27/2016
Akcea Therapeutics Announces Publication Of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides And Improved Insulin Sensitivity In Patients With High Triglycerides And Type 2 Diabetes 6/27/2016
Santalis Announces Positive Results From A Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation For The Treatment Of Mild-To-Moderate Plaque Psoriasis 6/27/2016
TWi Biotechnology Announces Last Patient Enrolled In Phase 2 Study Of AC-201CR For Gout Treatment 6/27/2016
Stealth Biotherapeutics Initiates Two Phase 2 Trials Evaluating Elamipretide For The Treatment Of Heart Failure 6/27/2016
Alnylam (ALNY) To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis 6/27/2016
Neurotrope Announces That A New Study Published In The Journal of Biological Chemistry Shows That Bryostatin, A PKC Epsilon Activator, Generates New Synapses Through Accumulation Of The Synaptic Anchoring Protein PSD-95 At Neuronal Membranes 6/23/2016
Reata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase II LARIAT Study In Pulmonary Arterial Hypertension 6/23/2016
Wilson Therapeutics Presents Preliminary Clinical Data On Decuprate At The 20th International Congress Of Parkinson's Disease And Movement Disorders 6/23/2016
BioCon (BIOCON.NS), Quark Pharmaceuticals Inc. Announce Initiation Of Pivotal Phase II/III Study Of QPI-1007 In Rare Eye Disease In India 6/23/2016
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed In Phase 2a Expansion Stage Evaluating CRLX301 In Patients With Advanced Solid Tumors 6/23/2016
Taiwan Liposome Company Completes Trial Enrollment For Arthritis Treatment 6/23/2016
Wilson Therapeutics Presents Preliminary Clinical Data On Decuprate At The 20th International Congress Of Parkinson´s Disease And Movement Disorders 6/23/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Two Upstarts that Could Dislodge Gilead (GILD)'s Hold on the Hepatitis C Market 6/22/2016
AXON Neuroscience’s Pioneering Tau Vaccine Against Alzheimer's Started Phase II 6/22/2016
Frontier Biotechnologies Reports Primary Endpoint Met In Phase 2 Trial Of AB001 In Chronic Low Back Pain 6/22/2016
ASM Microbe 2016 Presentation of Clinical Results From CytoDyn (CYDY)’s Phase IIb Monotherapy Extension Study Now Available 6/22/2016
Prima Biomed (PRR.AX) Announces First Safety, Pharmacokinetics And Immuno-Monitoring Data From Phase IIb Clinical Trial Of IMP321 6/22/2016
Ardelyx (ARDX) Reports Progress Of Development Programs 6/22/2016
ViaCyte To Present At ISSCR 2016 Annual Meeting 6/22/2016
Epizyme (EPZM) to Continue Blood Cancer Trials as Tumors Were Wiped Out in Some Patients 6/21/2016
Ascletis, Inc. Publishes Interim Data Of Phase II Study In Taiwan For Its Interferon-Free HCV Regimen 6/21/2016
AiVita Biomedical Receives FDA Approval For Phase II Ovarian Cancer Treatment 6/21/2016
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016
ContraVir Doses First Patients In Head-To-Head Study Of CMX157 Vs. Viread For Treating Hepatitis B 6/21/2016
TapImmune (TPIV) Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200 6/21/2016
Trek Therapeutics Initiates Phase 2a Study Of Faldaprevir And TD-6450, With And Without Ribavirin, In Patients With HCV GT 1b. 6/21/2016
Oramed (ORMP) Announces $6.5 Million Milestone Payment From HTIT 6/21/2016
Global Blood Therapeutics (GBT) Announces Pricing Of Public Offering Of Common Stock 6/21/2016
Asterias Biotherapeutics Announces Oral Presentation And Participation In Panel Discussion At The ISSCR 14th Annual Meeting 6/21/2016
Results Of Phase II Study Of Merck & Co. (MRK)’s Investigational Beta-Lactamase Inhibitor Relebactam In Combination With Imipenem/Cilastatin Presented At ASM Microbe 6/20/2016
TiGenix Announces Six-Month Phase I/II Results Of Allocsc-01 In Acute Myocardial Infarction 6/20/2016
Seres Therapeutics Presents New Data At ASM Microbe 2016, Including Characterization Of SER-262, The Rationally-Designed, Fermented Microbiome Therapeutic Candidate For Primary Clostridium Difficile Infection 6/20/2016
Epizyme (EPZM) Reports Early Data From Global Phase 2 Trial Of Tazemetostat In Non-Hodgkin Lymphoma At American Society of Hematology Lymphoma Biology Meeting 6/20/2016
Global Blood Therapeutics (GBT) Announces Initiation Of Phase 2a Study Of GBT440 In Idiopathic Pulmonary Fibrosis 6/20/2016
Takeda (TKPYY) Initiates World’s First Norovirus Vaccine Field Trial 6/20/2016
Hutchison China MediTech (Chi-Med) Release: Savolitinib Global Phase II Trial Initiated In EGFR Mutant Non-Small Cell Lung Cancer 6/20/2016
Medgenics, Inc. Announces Enrollment Of First Patient In Phase 2/3 Clinical Trial Of NFC-1 In Adolescents With mGluR Mutation Positive ADHD 6/17/2016
Tobira’s Cenicriviroc Shown To Reduce Liver Injury In Independent Research Published In The Journal Hepatology 6/17/2016
MorphoSys AG Reports Publication Of Clinical Case Report Of A Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission Of Currently 26 Months Under MOR208 Treatment 6/17/2016
CytoDyn (CYDY)n’s PRO 140 Phase IIb HIV Monotherapy Trial Findings To Be Presented At ASM Microbe 2016 Conference On June 20 6/17/2016
Arsanis Presents Data At ASM Microbe 2016 Demonstrating Protection Against Multidrug-Resistant Escherichia Coli And Klebsiella Pneumoniae Using Monoclonal Antibody Technology 6/17/2016
Pfizer (PFE) Head of R&D Talks Strategy on How Pharma Chooses Compounds to Bet A Billion Dollars On 6/16/2016
OncoSec Medical Presents Preliminary Findings From Head And Neck Phase II Clinical Trial At EUROGIN 2016 Conference 6/16/2016
NLS Pharma Release: FDA Accepts IND For Phase II Study Of Mazindol In Adults With ADHD 6/16/2016
Shire (SHPG) Nabs Breakthrough Tags for Drug to Treat Rare Gastrointestinal Conditions 6/15/2016
Noveome Initiates Phase II Clinical Trial Of ST266 To Treat Patients With Periodontitis 6/15/2016
Flex Pharma (FLKS) Initiates Phase II Efficacy Study In Multiple Sclerosis 6/15/2016
Hansa Medical: Successful Desensitization With IdeS In All Recruited Patients In Ongoing U.S. Phase II Study 6/15/2016
Immune Pharma Expands Its Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid To Six Academic Institutions In The United States 6/15/2016
European Society of Cardiology Selects CardioCell's Heart Failure (HF) Study Results For ESC Congress 2016 Late-Breaking Science Session 6/15/2016
Soterix Medical Awarded $2.5 Million NIH Grant To Run Phase-II Efficacy Trial To Treat Aphasia After Stroke With HD-Tdcs 6/15/2016
Amoy Diagnostics Co. LTD. ROS1 Diagnostics Test Contributed To A Phase 2 Clinical Study Of Crizotinib In Lung Cancer 6/15/2016
Infinity Pharma (INFI) to Eliminate 46 Researchers After Lymphoma Drug Disappoints in Study 6/14/2016
vTv Therapeutics Presents Positive Results From A Pilot Study Of Its Glucokinase Activator At American Diabetes Association 76th Scientific Sessions 6/14/2016
Eiger Biopharma Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia 6/14/2016
Janssen R&D Release: Canagliflozin Phase 2 Study Demonstrates Glycemic Improvements In Adults With Type 1 Diabetes 6/14/2016
The Medicines Company (MDCO) Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700 6/14/2016
City of Hope Release: Autologous Stem Cell Transplantation Offers Safe And Effective, And Potentially Curative, Option For Patients With HIV-Associated Lymphoma 6/14/2016
Agios (AGIO)' Anemia Drug Data Hits Mark in Mid-Stage Study 6/13/2016
Zafgen (ZFGN) Presents New Data From The Phase IIb Clinical Trial Evaluating Beloranib In Severe Obesity Complicated By Type 2 Diabetes At The American Diabetes Association's 76th Scientific Sessions 6/13/2016
Melior Pharmaceuticals Announces Positive Phase IIA Results In Type 2 Diabetes Study 6/13/2016
Acetylon Pharmaceuticals Presents Data On The Use Of HDAC6 Inhibitors Ricolinostat (ACY-1215) And ACY-241 In Combination With Pomalidomide And Dexamethasone For The Treatment Of Multiple Myeloma 6/13/2016
Ariad (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase II Pace Clinical Trial 6/13/2016
Aerpio Reports Peer-Reviewed Publication Of Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial 6/13/2016
Aimmune (AIMT) Announces Phase II Extended Maintenance Data Supporting Safety And Tolerability Profile Of AR101 For Peanut Allergy 6/13/2016
Janssen R&D Release: New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management 6/13/2016
BioSpecifics Technologies Corporation (BSTC) Announces Positive Top-Line Results From Phase 2 Trial Of CCH For Treatment Of Human Lipoma 6/13/2016
Galena Biopharma  (GALE) Receives Two Orphan Drug Designations For GALE-301 And GALE-301/GALE-302 6/13/2016
Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due To The Targeting Of MCL-1 6/13/2016
Poxel Presents New Data On Imeglimin’s Dual Mechanism Of Action At The American Diabetes Association’s 76th Scientific Sessions 6/13/2016
Global Blood Therapeutics (GBT) Stock Surges on Promising Sickle Cell Drug Results 6/10/2016
Sophiris Bio (SPHS) Reports Successful Results From Completed Phase 2a Study Of Topsalysin In Localized Prostate Cancer 6/10/2016
Data In The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase In Overall Survival In Patients With Advanced Soft Tissue Sarcoma, As Reported By Eli Lilly (LLY) And Memorial Sloan-Kettering Cancer Center Researchers 6/10/2016
Acceleron Pharma And Celgene (CELG) Announce Updated Results From An Ongoing Phase II Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association 6/10/2016
Acceleron Pharma And Celgene (CELG) Announce Updated Results From An Ongoing Phase II Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association 6/10/2016
Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity Of Its Lead Drug Candidates At 21st Congress Of The European Hematology Association 6/10/2016
New Data On Bristol-Myers Squibb (BMY)'s Opdivo (Nivolumab) Indicate Benefit In Heavily Pre-Treated Classical Hodgkin Lymphoma Patients In Phase II, Single-Arm Pivotal Trial 6/10/2016
Prothena (PRTA) Presents First Clinical Data for PRX003 for the Treatment of Inflammatory Diseases 6/10/2016
NuSirt Presenting New Research At American Diabetes Association’s 76th Annual Scientific Sessions 6/10/2016
AVANIR (AVNR) To Present Data On ONZETRA Xsail At American Headache Society (AHS) 2016 Annual Scientific Meeting 6/10/2016
Amgen (AMGN) Shows Off Mid-Stage Migraine Data, Needs to Compete With Eli Lilly (LLY), Teva (TEVA) and Alder Biopharma 6/9/2016
Paradigm Provides Clinical Trial Update 6/9/2016